OraSure Technologies, Inc. (NASDAQ:OSUR) has earned an average recommendation of “Sell” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $10.00.
A number of research analysts recently weighed in on OSUR shares. BidaskClub raised OraSure Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $16.00 price objective on shares of OraSure Technologies in a report on Thursday, February 7th. Zacks Investment Research lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, ValuEngine lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Monday, February 4th.
In other news, CFO Roberto Cuca bought 10,000 shares of the stock in a transaction on Friday, May 10th. The shares were bought at an average price of $9.03 per share, with a total value of $90,300.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephen S. Phd Tang sold 16,667 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $11.10, for a total value of $185,003.70. Following the completion of the sale, the chief executive officer now directly owns 135,627 shares in the company, valued at approximately $1,505,459.70. The disclosure for this sale can be found here. Insiders acquired 21,000 shares of company stock worth $184,360 in the last three months. 1.70% of the stock is owned by corporate insiders.
OSUR stock traded down $0.16 on Thursday, reaching $8.23. 23,849 shares of the company’s stock were exchanged, compared to its average volume of 1,063,512. OraSure Technologies has a twelve month low of $8.17 and a twelve month high of $17.97. The firm has a market capitalization of $520.60 million, a PE ratio of 16.44, a P/E/G ratio of 2.95 and a beta of 1.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.52 and a quick ratio of 6.56.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. OraSure Technologies had a return on equity of 7.87% and a net margin of 11.34%. The firm had revenue of $30.12 million for the quarter, compared to analyst estimates of $29.66 million. During the same quarter in the prior year, the company posted $0.07 earnings per share. OraSure Technologies’s quarterly revenue was down 28.3% on a year-over-year basis. Equities research analysts expect that OraSure Technologies will post 0.23 earnings per share for the current fiscal year.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Further Reading: What is the formula for calculating total return?
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.